<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Glycoconj J</journal-id>
      <journal-title>Glycoconjugate Journal</journal-title>
      <issn pub-type="ppub">0282-0080</issn>
      <issn pub-type="epub">1573-4986</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17909966</article-id>
      <article-id pub-id-type="pmc">2234449</article-id>
      <article-id pub-id-type="publisher-id">9070</article-id>
      <article-id pub-id-type="doi">10.1007/s10719-007-9070-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Characterization of anticoagulant heparinoids by immunoprofiling</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wijnhoven</surname>
            <given-names>Tessa J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>van de Westerlo</surname>
            <given-names>Els M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smits</surname>
            <given-names>Nicole C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lensen</surname>
            <given-names>Joost F.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rops</surname>
            <given-names>Angelique L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>van der Vlag</surname>
            <given-names>Johan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Berden</surname>
            <given-names>Jo H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>van den Heuvel</surname>
            <given-names>Lambert P.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>van Kuppevelt</surname>
            <given-names>Toin H.</given-names>
          </name>
          <address>
            <phone>+31-24-3616759</phone>
            <fax>+31-24-3540339</fax>
            <email>A.vankuppevelt@ncmls.ru.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Matrix Biochemistry, Nijmegen Centre for Molecular Life Sciences, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Department of Pediatric Nephrology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands </aff>
        <aff id="Aff3"><label>3</label>Nephrology Research Laboratory, Division of Nephrology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>10</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <volume>25</volume>
      <issue>2</issue>
      <fpage>177</fpage>
      <lpage>185</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>5</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>8</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>8</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer Science+Business Media, LLC 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Heparinoids are used in the clinic as anticoagulants. A specific pentasaccharide in heparinoids activates antithrombin III, resulting in inactivation of factor Xa and&#x2013;when additional saccharides are present&#x2013;inactivation of factor IIa. Structural and functional analysis of the heterogeneous heparinoids generally requires advanced equipment, is time consuming, and needs (extensive) sample preparation. In this study, a novel and fast method for the characterization of heparinoids is introduced based on reactivity with nine unique anti-heparin antibodies. Eight heparinoids were biochemically analyzed by electrophoresis and their reactivity with domain-specific anti-heparin antibodies was established by ELISA. Each heparinoid displayed a distinct immunoprofile matching its structural characteristics. The immunoprofile could also be linked to biological characteristics, such as the anti-Xa/anti-IIa ratio, which was reflected by reactivity of the heparinoids with antibodies HS4C3 (indicative for 3-<italic>O</italic>-sulfates) and HS4E4 (indicative for domains allowing anti-factor IIa activity). In addition, the immunoprofile could be indicative for heparinoid-induced side-effects, such as heparin-induced thrombocytopenia, as illustrated by reactivity with antibody NS4F5, which defines a very high sulfated domain. In conclusion, immunoprofiling provides a novel, fast, and simple methodology for the characterization of heparinoids, and allows high-throughput screening of (new) heparinoids for defined structural and biological characteristics.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Antibody</kwd>
        <kwd>Anticoagulation</kwd>
        <kwd>Heparin-induced thrombocytopenia</kwd>
        <kwd>Heparinoid</kwd>
        <kwd>Immunoprofiling</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media, LLC 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Glycosaminoglycans (GAGs) are long, unbranched, negatively charged polysaccharide chains. The precursor of heparin and heparan sulfate (HS) is composed of alternating <italic>N</italic>-acetylglucosamine (GlcNAc) and <sc>d</sc>-glucuronic acid (GlcA) residues. In chondroitin sulfate (CS) and dermatan sulfate (DS), the aminosugar is a <italic>N</italic>-acetylgalactosamine (GalNAc) instead of GlcNAc. The polysaccharide chain precursors are modified by a sequential series of enzymatic reactions, including <italic>N</italic>-deacetylation/<italic>N</italic>-sulfation, C5-epimerization of GlcA to <sc>l</sc>-iduronic acid (IdoA), and <italic>O</italic>-sulfation at various positions [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p>
      <p>Heparin is widely used as an anticoagulant. A specific pentasaccharide sequence (GlcNAc/NS(6O<italic>S</italic>)&#x2013;GlcA&#x2013;GlcN<italic>S</italic>(3,6O<italic>S</italic>)&#x2013;IdoA(2O<italic>S</italic>)&#x2013;GlcN<italic>S</italic>(6O<italic>S</italic>)) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] in heparin binds with high affinity to the enzyme inhibitor antithrombin III, causing a conformational change, resulting in the exposition of its active sites and in inactivation of factor Xa. For the inactivation of factor IIa, an additional site in heparin proximal to the pentasaccharide is necessary. The formation of a ternary complex between antithrombin III, factor IIa and heparin, which requires at least 18 saccharide residues for efficient formation, subsequently results in the inactivation of factor IIa [<xref ref-type="bibr" rid="CR23">23</xref>]. Next to heparin, other heparinoids are used, including preparations containing other GAGs such as HS and DS, low molecular weight heparins (LMWHs), and fondaparinux, a synthetic pentasaccharide identical in structure to the antithrombin III-binding pentasaccharide. Heparinoids are used to treat patients with venous thrombosis and pulmonary embolism [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In addition, they are used to prevent thrombosis in patients that undergo surgery and to prevent clotting in the extracorporeal circulation during hemodialysis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Due to their lower molecular weight, LMWHs have a high anti-factor Xa activity compared to their anti-factor IIa activity resulting in a more refined regulation of coagulation [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In addition, the biological half-life of LMWHs/fondaparinux is longer in comparison to heparin, and the incidence of heparin-induced thrombocytopenia (HIT) is substantially reduced [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p>
      <p>LMWHs are synthesized from heparin by controlled chemical or enzymatic depolymerization processes, resulting in the production of oligosaccharides of various lengths (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Dalteparin and nadroparin are produced by deamination using nitrous acid, resulting in the formation of an unnatural 2,5-anhydromannitol residue at the reducing end of the resulting oligosaccharides. Enoxaparin is produced by chemical &#x3B2;-elimination at alkaline pH, whereas tinzaparin is produced by enzymatic &#x3B2;-elimination by heparinase. Both processes result in the formation of an unsaturated uronic acid residue at the non-reducing end of the GAG fragments [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Characteristics of therapeutic heparinoids</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Heparinoid: generic name (brand name)</th><th>Composition (and method of heparin modification)</th><th>Molecular weight, kDa</th></tr></thead><tbody><tr><td>Heparin</td><td>Heparin</td><td>5.0&#x2013;30.0</td></tr><tr><td>Dalteparin (Fragmin)</td><td>LMWH (deaminative cleavage with nitrous acid)</td><td>4.0&#x2013;6.0</td></tr><tr><td>Nadroparin (Fraxiparine)</td><td>LMWH (deaminative cleavage with nitrous acid)</td><td>2.4&#x2013;7.2</td></tr><tr><td>Enoxaparin (Clexane, Lovenox)</td><td>LMWH (&#x3B2;-eliminative cleavage by alkaline treatment)</td><td>3.5&#x2013;5.5</td></tr><tr><td>Tinzaparin (Innohep, Logiparin)</td><td>LMWH (&#x3B2;-eliminative cleavage by heparinase)</td><td>3.4&#x2013;5.6</td></tr><tr><td>Sulodexide (Vessel Due F)</td><td>80% &#x2018;fast-moving&#x2019; heparin<sup>a</sup>, 20% DS</td><td>&lt;8.0</td></tr><tr><td>Danaparoid (Orgaran)</td><td>84% HS, 12% DS, 4% CS</td><td>4.0&#x2013;10.0</td></tr><tr><td>Fondaparinux (Arixtra)</td><td>Pentasaccharide: C<sub>31</sub>H<sub>43</sub>N<sub>3</sub>Na<sub>10</sub>S<sub>8</sub></td><td>1,728</td></tr></tbody></table><table-wrap-foot><p>All drugs are derived from porcine intestinal mucosa, with the exception of the chemically synthesized pentasaccharide fondaparinux.</p><p><italic>LMWH</italic> Low-molecular weight heparin, <italic>HS</italic> heparan sulfate, <italic>DS</italic> dermatan sulfate, <italic>CS</italic> chondroitin sulfate</p><p><sup>a</sup>Heparin that is less sulfated and has a lower molecular weight [<xref ref-type="bibr" rid="CR42">42</xref>].</p></table-wrap-foot></table-wrap></p>
      <p>All heparinoids, with the exception of fondaparinux, are heterogeneous mixtures of different GAG chains. Structural analysis of heparinoids is generally done by nuclear magnetic resonance spectroscopy, high pressure liquid chromatography, mass spectrometry, capillary electrophoresis, or polyacrylamide gel electrophoresis [<xref ref-type="bibr" rid="CR17">17</xref>]. In general, these techniques require sophisticated instrumentation and sometimes extensive sample preparation. Alternative methodologies that are fast and simple are needed. Immunoprofiling of heparinoids could be a fast and simple method to characterize the complex heparinoids. Recently, a number of phage&#x2013;display-derived antibodies were generated, reactive with various domain structures within heparin. In this study nine antibodies&#x2013;all defining different heparin epitopes&#x2013;were applied to study their reactivity with heparinoids.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Heparinoids</title>
        <p>The following heparinoids were included in the study: heparin (Sigma, St. Louis, MO), dalteparin (Pharmacia, Woerden, The Netherlands), nadroparin (Sanofi-Synth&#xE9;labo, Maassluis, The Netherlands), enoxaparin (Aventis Pharma, Hoevelaken, The Netherlands), tinzaparin (LEO Pharma, Breda, The Netherlands), sulodexide (Alfa Wassermann S.p.A., Bologna, Italy), danaparoid (Organon, Oss, The Netherlands), and fondaparinux (Sanofi-Synth&#xE9;labo, Maassluis, The Netherlands). Characteristics are given in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.</p>
      </sec>
      <sec id="Sec4">
        <title>Quantification of glycosaminoglycans by Farndale assay</title>
        <p>A Farndale assay was done to determine the concentration of GAGs in the preparations [<xref ref-type="bibr" rid="CR13">13</xref>]. To 50&#xA0;&#x3BC;l of the standard (heparin, 0&#x2013;100&#xA0;&#x3BC;g/ml) and heparinoids 1&#xA0;ml Farndale reagent (40.5&#xA0;mmol/l glycine, 40.6&#xA0;mmol/l NaCl, and 0.05&#xA0;mmol/l 1,9-dimethylmethylene blue, pH&#xA0;3.0) was added and absorbance was measured directly at 525&#xA0;nm.</p>
      </sec>
      <sec id="Sec5">
        <title>Determination of glycosaminoglycan classes by agarose gel electrophoresis</title>
        <p>The different classes of GAGs in the heparinoids were separated by agarose gel electrophoresis, fixed in 0.1% (<italic>w</italic>/<italic>v</italic>) azure A in 10&#xA0;mmol/l MgCl<sub>2</sub>&#xB7;6H<sub>2</sub>O, 50&#xA0;mmol/l Na&#x2013;formiate and 0.001% (<italic>w</italic>/<italic>v</italic>) Na&#x2013;azide (pH&#xA0;3.5), and stained by combined azure A&#x2013;silver treatment [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Enzymatic digestion of heparinoids</title>
        <p>Heparinoids were diluted in heparinase I digestion buffer (50&#xA0;mmol/l NaAc and 50&#xA0;mmol/l Ca(Ac)<sub>2</sub>, pH&#xA0;7.0) and/or chondroitinase ABC digestion buffer (25&#xA0;mmol/l Tris and 2&#xA0;mmol/l Mg(Ac)<sub>2</sub>, pH&#xA0;8.0) to a final content of 4&#xA0;mg/ml. The enzymes were added to a final concentration of 0.02&#xA0;IU/ml for heparinase I (E.C. 4.2.2.7; from <italic>Flavobacterium heparinum</italic>; Seikagaku, Tokyo, Japan) and 0.04&#xA0;IU/ml for chondroitinase ABC (E.C. 4.2.2.4; from <italic>Proteus vulgaris</italic>; Sigma). Heparinase I cleaves the linkages GlcNS&#xB1;6S&#x2013;IdoA2S predominantly present in heparin and to a minor extent in HS [<xref ref-type="bibr" rid="CR11">11</xref>]. Chondroitinase ABC cleaves CS and DS [<xref ref-type="bibr" rid="CR11">11</xref>]. The solutions were incubated for 16&#xA0;h at 37&#xB0;C.</p>
      </sec>
      <sec id="Sec7">
        <title>Determination of glycosaminoglycan size by polyacrylamide gel electrophoresis</title>
        <p>Heparinoids and their enzymatic digestion products were separated by polyacrylamide gel electrophoresis using a 33% gel [<xref ref-type="bibr" rid="CR36">36</xref>], fixed in 0.8% (<italic>w</italic>/<italic>v</italic>) alcian blue in 2% (<italic>v</italic>/<italic>v</italic>) HAc, and stained by combined azure A&#x2013;silver treatment [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
      </sec>
      <sec id="Sec8">
        <title>Production of anti-heparin antibodies</title>
        <p>Antibodies (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) were obtained by biopanning against HS or heparin, using bovine kidney HS (antibodies HS4C3 [<xref ref-type="bibr" rid="CR41">41</xref>], HS3A8, HS4E4 [<xref ref-type="bibr" rid="CR8">8</xref>], and LKIV69 [<xref ref-type="bibr" rid="CR43">43</xref>]), porcine intestinal mucosa heparin (antibodies EW3D10 and EW4G2 [<xref ref-type="bibr" rid="CR39">39</xref>]), human lung HS (antibody NS4F5; Smits <italic>et al.</italic>, unpublished results), and mouse and human skeletal muscle GAG (antibodies AO4B08 and RB4EA12 [<xref ref-type="bibr" rid="CR15">15</xref>], respectively). Large scale production of soluble antibodies was performed as described before [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Characteristics of epitope-specific anti-heparin antibodies</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antibody</th><th>V<sub>H</sub> CDR3 sequence</th><th>V<sub>H</sub> family</th><th>DP gene</th><th>GAG used for selection</th><th>Essential modifications</th><th>Inhibitory modifications</th></tr></thead><tbody><tr><td rowspan="4">HS4C3</td><td rowspan="4">GRRLKD</td><td rowspan="4">3</td><td rowspan="4">38</td><td rowspan="4">Bovine kidney HS [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td><italic>N</italic>-sulfation</td><td rowspan="4">&#xA0;</td></tr><tr><td>2-<italic>O</italic>-sulfation (minor importance)</td></tr><tr><td>6-<italic>O</italic>-sulfation</td></tr><tr><td>3-<italic>O</italic>-sulfation</td></tr><tr><td rowspan="4">HS3A8</td><td rowspan="4">GMRPRL</td><td rowspan="4">3</td><td rowspan="4">38</td><td rowspan="4">Bovine kidney HS [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td><italic>N</italic>-sulfation</td><td rowspan="4">&#xA0;</td></tr><tr><td>C5-epimerization</td></tr><tr><td>2-<italic>O</italic>-sulfation</td></tr><tr><td>6-<italic>O</italic>-sulfation (likely)</td></tr><tr><td rowspan="3">HS4E4</td><td rowspan="3">HAPLRNTRTNT</td><td rowspan="3">3</td><td rowspan="3">38</td><td rowspan="3">Bovine kidney HS [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td><italic>N</italic>-acetylation</td><td rowspan="3">2-<italic>O</italic>-sulfation<sup>a</sup> 6-<italic>O</italic>-sulfation</td></tr><tr><td><italic>N</italic>-sulfation</td></tr><tr><td>C5-epimerization</td></tr><tr><td rowspan="3">LKIV69</td><td rowspan="3">GSRSSR</td><td rowspan="3">3</td><td rowspan="3">38</td><td rowspan="3">Bovine kidney HS [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td><italic>N</italic>-sulfation</td><td rowspan="3">6-<italic>O</italic>-sulfation</td></tr><tr><td>C5-epimerization (likely)</td></tr><tr><td>2-<italic>O</italic>-sulfation</td></tr><tr><td>EW3D10</td><td>GRTVGRN</td><td>3</td><td>38</td><td>Porcine intestinal mucosa heparin [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td>Sulfation required, position(s) unknown<sup>b</sup></td><td/></tr><tr><td>EW4G2</td><td>GKVKLPN</td><td>3</td><td>38</td><td>Porcine intestinal mucosa heparin [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td>Sulfation required, position(s) unknown<sup>b</sup></td><td/></tr><tr><td rowspan="4">NS4F5</td><td rowspan="4">SGRKGRMR</td><td rowspan="4">3</td><td rowspan="4">53</td><td rowspan="4">Human lung HS<sup>c</sup></td><td><italic>N</italic>-sulfation</td><td rowspan="4">&#xA0;</td></tr><tr><td>C5-epimerization</td></tr><tr><td>2-<italic>O</italic>-sulfation (high)</td></tr><tr><td>6-<italic>O</italic>-sulfation (high)</td></tr><tr><td rowspan="4">AO4B08</td><td rowspan="4">SLRMNGWRAHQ</td><td rowspan="4">3</td><td rowspan="4">47</td><td rowspan="4">Mouse skeletal muscle GAG [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td><italic>N</italic>-sulfation</td><td rowspan="4">&#xA0;</td></tr><tr><td>C5-epimerization</td></tr><tr><td>2-<italic>O</italic>-sulfation<sup>d</sup></td></tr><tr><td>6-<italic>O</italic>-sulfation (high)</td></tr><tr><td rowspan="3">RB4EA12</td><td rowspan="3">RRYALDY</td><td rowspan="3">3</td><td rowspan="3">32</td><td rowspan="3">Human skeletal muscle GAG [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td><italic>N</italic>-acetylation</td><td rowspan="3">&#xA0;</td></tr><tr><td><italic>N</italic>-sulfation</td></tr><tr><td>6-<italic>O</italic>-sulfation</td></tr><tr><td>MPB49 (control)</td><td>WRNDRQ</td><td>3</td><td>38</td><td>&#x2013;</td><td>&#x2013;</td><td/></tr></tbody></table><table-wrap-foot><p>Given are the antibody name, amino acid sequence of the V<sub>H</sub> complementary determining region 3 (CDR3), V<sub>H</sub> germ line gene family, DP gene number, selection moiety, and relevant modification reactions required for antibody binding. Table derived from Wijnhoven <italic>et al.</italic> unpublished results.</p><p><italic>GAG</italic> Glycosaminoglycan, <italic>HS</italic> heparan sulfate</p><p><sup>a</sup>Antibody HS4E4 possibly requires as yet unspecified <italic>O</italic>-sulfated residues [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p><sup>b</sup>Although the chemical nature of the specific heparin/HS structure recognized is not exactly known, the antibody defines a unique sulfated heparin/HS structure as demonstrated by its specific staining pattern on renal cryosections [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p><sup>c</sup>Smits <italic>et al.</italic>, unpublished results</p><p><sup>d</sup>Antibody AO4B08 requires an internal 2-<italic>O</italic>-sulfated iduronic acid residue [<xref ref-type="bibr" rid="CR16">16</xref>].</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec9">
        <title>Enzyme-linked immunosorbent assay</title>
        <p>Reactivity of the anti-heparin antibodies with the heparinoids was evaluated by enzyme-linked immunosorbent assay (ELISA). Wells of microtiter plates were coated overnight by incubation with the heparinoids that bound by passive adsorption [<xref ref-type="bibr" rid="CR41">41</xref>]. After blocking with PBS containing 3% (<italic>w</italic>/<italic>v</italic>) BSA and 1% (<italic>v</italic>/<italic>v</italic>) Tween-20 for 1&#xA0;h, anti-heparin antibodies [in PBS containing 1% (<italic>w</italic>/<italic>v</italic>) BSA and 0.1% (<italic>v</italic>/<italic>v</italic>) Tween-20] were added for 1.5&#xA0;h. As a negative control, antibody MPB49 was used, which is &gt;95% identical to most antibodies used, but does not bind any GAG. Bound antibodies were detected using mouse IgG anti-VSV tag antibody P5D4 (1:10; Boehringer Mannheim, Mannheim, Germany), followed by incubation with alkaline phosphatase-conjugated rabbit anti-mouse IgG (1:2,000; Dako, Glostrup, Denmark), both for 1&#xA0;h. Enzyme activity was detected using 100&#xA0;&#x3BC;l 1&#xA0;mg <italic>p</italic>-nitrophenyl phosphate (ICN, Aurora, OH)/ml 1&#xA0;M diethanolamine/0.5&#xA0;mM MgCl<sub>2</sub> (pH&#xA0;9.8) as a substrate. Absorbance was measured at 405&#xA0;nm [<xref ref-type="bibr" rid="CR43">43</xref>]. Background reactivity, measured with the control antibody MPB49, was substracted. The absorbance with control antibody MPB49 was comparable to the absorbance measured when primary antibody was omitted.</p>
      </sec>
      <sec id="Sec10">
        <title>Immunofluorescence staining</title>
        <p>Human kidney cryosections (2&#xA0;&#x3BC;m) were incubated with anti-heparin antibodies in the absence or presence of 100&#xA0;&#x3BC;g/ml of the heparinoids. Bound antibodies were detected as described [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec11" sec-type="results">
      <title>Results</title>
      <sec id="Sec12">
        <title>General biochemical analysis of heparinoids</title>
        <p>The different classes of GAGs in the heparinoids were separated by agarose gel electrophoresis (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Heparin showed a band at about the same position as the HS standard, whereas the LMWHs dalteparin, nadroparin, enoxaparin, and tinzaparin migrated somewhat further into the gel. Danaparoid displayed bands at the level of HS and DS, whereas the CS band, which only represents 4% of the prepration (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>), could not be detected. Sulodexide clearly showed two bands, representing the &#x2018;fast-moving&#x2019; heparin (heparin that is less sulfated and has a lower molecular weight [<xref ref-type="bibr" rid="CR42">42</xref>]) and DS fractions. The chemically synthesized pentasaccharide fondaparinux, which has a much lower molecular weight compared to the other heparinoids, migrated further into the gel.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Agarose gel electrophoresis of heparinoids. The different classes of GAGs in the drugs were visualized by a combined azure A&#x2013;silver staining procedure. The standard contains 40&#xA0;ng HS, 20&#xA0;ng DS, and 20&#xA0;ng CS</p></caption><graphic position="anchor" xlink:href="10719_2007_9070_Fig1_HTML" id="MO1"/></fig></p>
        <p>To analyze the molecular range of the heparinoids, gel electrophoresis using 33% polyacrylamide was applied. The LMWHs clearly displayed distinct fragments with a lower molecular weight compared to heparin (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a). The smaller fragments of enoxaparin compared to tinzaparin (both prepared by &#x3B2;-elimination) can be explained by a preference of heparinase for 2-<italic>O</italic>-sulfated iduronic acid in contrast to chemical alkaline treatment, which results in cleavage at both sulfated and non-sulfated iduronic acid residues. Sulodexide and danaparoid showed a broad smear with less distinct fragments, in line with their methods of preparation, which does not include a specific depolymerization step. The pentasaccharide fondaparinux demonstrated primarily one individual band. To further establish the nature of the heparinoids, they were subjected to enzymatic digestion using heparinase I and/or chondroitinase ABC (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b for dalteparin, enoxaparin, and sulodexide). Heparin, dalteparin, nadroparin, enoxaparin, tinzaparin, and fondaparinux were only cleaved by heparinase I, in accordance with their derivation from heparin. Sulodexide was cleaved by heparinase I as well as chondroitinase ABC, which is in line with the heparin/DS nature of the preparation. Danaparoid was primarily cleaved by chondroitinase ABC, reflecting the presence of DS/CS, whereas heparinase I was less effective.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Thirty-three percent polyacrylamide gel electrophoresis of undigested (<bold>a</bold>) and enzymatically digested (<bold>b</bold>) heparinoids. Heparinoids were visualized by a combined alcian blue-silver staining procedure. Treatment with heparinase I resulted in cleavage of dalteparin and enoxaparin, whereas treatment with chondroitinase ABC did not. Sulodexide was cleaved by heparinase I as well as chondroitinase ABC</p></caption><graphic position="anchor" xlink:href="10719_2007_9070_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec13">
        <title>Characterization of heparinoids using anti-heparin antibodies</title>
        <p>Reactivity of anti-heparin antibodies with immobilized heparinoids was analyzed by ELISA (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>). For reference, reactivity of antibodies with heparin was set at 100%. A distinct antibody-binding profile could be observed for all antibodies, although also similar reactivity with a number of antibodies was noticed. For instance, enoxaparin and tinzaparin, both prepared by &#x3B2;-elimination, reacted differently with antibodies LKIV69 and EW4G2, whereas they reacted similarly with the other antibodies. Nadroparin reacted very poorly with all the antibodies tested, which may be in line with its overall low amount of sulfated disaccharides in comparison with other LMWHs [<xref ref-type="bibr" rid="CR17">17</xref>]. In contrast, sulodexide and danaparoid reacted strongly with antibody HS4E4, which defines a low-sulfated and <italic>N</italic>-acetylated epitope, in comparison to the LMWHs. This is in line with the presence of low-sulfated heparin (HS) and HS in sulodexide and danaparoid, respectively, and which contain a substantial amount of <italic>N</italic>-acetylated glucosamine. Compared to heparin, the other heparinoids reacted poorly with antibody NS4F5, which defines a very highly sulfated oligosaccharide.
<table-wrap id="Tab3"><label>Table&#xA0;3</label><caption><p>Reactivity of anti-heparin antibodies with heparinoids (ELISA)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#xA0;</th><th>HS4C3</th><th>HS3A8</th><th>HS4E4</th><th>LKIV69</th><th>EW3D10</th><th>EW4G2</th><th>NS4F5</th><th>AO4B08</th><th>RB4EA12</th></tr></thead><tbody><tr><td>Heparin</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td></tr><tr><td>Dalteparin</td><td>75&#x2009;&#xB1;&#x2009;6</td><td>44&#x2009;&#xB1;&#x2009;4</td><td>8&#x2009;&#xB1;&#x2009;5</td><td>3&#x2009;&#xB1;&#x2009;1</td><td>33&#x2009;&#xB1;&#x2009;6</td><td>49&#x2009;&#xB1;&#x2009;8</td><td>0&#x2009;&#xB1;&#x2009;0</td><td>16&#x2009;&#xB1;&#x2009;4</td><td>13&#x2009;&#xB1;&#x2009;2</td></tr><tr><td>Nadroparin</td><td>29&#x2009;&#xB1;&#x2009;3</td><td>5&#x2009;&#xB1;&#x2009;2</td><td>4&#x2009;&#xB1;&#x2009;3</td><td>0&#x2009;&#xB1;&#x2009;0</td><td>3&#x2009;&#xB1;&#x2009;1</td><td>7&#x2009;&#xB1;&#x2009;4</td><td>0&#x2009;&#xB1;&#x2009;0</td><td>1&#x2009;&#xB1;&#x2009;1</td><td>1&#x2009;&#xB1;&#x2009;1</td></tr><tr><td>Enoxaparin</td><td>80&#x2009;&#xB1;&#x2009;9</td><td>56&#x2009;&#xB1;&#x2009;8</td><td>7&#x2009;&#xB1;&#x2009;3</td><td>10&#x2009;&#xB1;&#x2009;2</td><td>36&#x2009;&#xB1;&#x2009;8</td><td>26&#x2009;&#xB1;&#x2009;7</td><td>1&#x2009;&#xB1;&#x2009;1</td><td>28&#x2009;&#xB1;&#x2009;7</td><td>21&#x2009;&#xB1;&#x2009;6</td></tr><tr><td>Tinzaparin</td><td>84&#x2009;&#xB1;&#x2009;1</td><td>55&#x2009;&#xB1;&#x2009;2</td><td>8&#x2009;&#xB1;&#x2009;3</td><td>44&#x2009;&#xB1;&#x2009;10</td><td>45&#x2009;&#xB1;&#x2009;12</td><td>74&#x2009;&#xB1;&#x2009;1</td><td>9&#x2009;&#xB1;&#x2009;2</td><td>20&#x2009;&#xB1;&#x2009;3</td><td>25&#x2009;&#xB1;&#x2009;8</td></tr><tr><td>Sulodexide</td><td>102&#x2009;&#xB1;&#x2009;5</td><td>71&#x2009;&#xB1;&#x2009;11</td><td>283&#x2009;&#xB1;&#x2009;21</td><td>51&#x2009;&#xB1;&#x2009;7</td><td>43&#x2009;&#xB1;&#x2009;10</td><td>100&#x2009;&#xB1;&#x2009;3</td><td>0&#x2009;&#xB1;&#x2009;0</td><td>102&#x2009;&#xB1;&#x2009;15</td><td>26&#x2009;&#xB1;&#x2009;8</td></tr><tr><td>Danaparoid</td><td>69&#x2009;&#xB1;&#x2009;11</td><td>22&#x2009;&#xB1;&#x2009;3</td><td>58&#x2009;&#xB1;&#x2009;17</td><td>2&#x2009;&#xB1;&#x2009;2</td><td>2&#x2009;&#xB1;&#x2009;1</td><td>1&#x2009;&#xB1;&#x2009;1</td><td>0&#x2009;&#xB1;&#x2009;0</td><td>63&#x2009;&#xB1;&#x2009;6</td><td>3&#x2009;&#xB1;&#x2009;1</td></tr></tbody></table><table-wrap-foot><p>Anti-heparin antibodies were applied to heparinoids immobilized on microtiter plates. Given is the reactivity of the antibodies with the heparinoids relative to unmodified heparin. Values are given as mean &#xB1; SEM (<italic>n</italic>&#x2009;=&#x2009;4). Each hepainoid shows a distinct immunoprofile.</p></table-wrap-foot></table-wrap></p>
        <p>Heparinoids could be ranked according to their reactivity with antibodies. For instance, reactivity of antibody EW4G2 was highest with heparin and sulodexide, followed by tinzaparin, dalteparin, and enoxaparin. Reactivity with the other heparinoids was very low or absent. Antibody LKIV69 reacted strongly with heparin, followed by sulodexide and tinzaparin, whereas other heparinoids reacted poorly. Reactivity of antibody AO4B08 was highest with heparin and sulodexide, followed by danaparoid and enoxaparin/tinzaparin/dalteparin, whereas reactivity with nadroparin was absent. These data indicate that distinct heparin domain structures are present in different commercially available heparinoids.</p>
        <p>The only chemically defined heparinoid studied was the pentasaccharide fondaparinux (GlcN<italic>S</italic>(6O<italic>S</italic>)&#x2013;GlcA&#x2013;GlcN<italic>S</italic>(3,6O<italic>S</italic>)&#x2013;IdoA(2O<italic>S</italic>)&#x2013;GlcN<italic>S</italic>(6O<italic>S</italic>)). Due to its small size (1,728&#xA0;kDa), it was assayed using a competition ELISA (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>). Heparin was included as a reference and values obtained for fondaparinux were related to those obtained for heparin. Antibodies HS4E4 and RB4EA12, both requiring <italic>N</italic>-acetylation in their epitopes, did not react with fondaparinux. Antibody NS4F5, which reacts with an extremely high sulfated oligosaccharide, was also not reactive. These results are in line with the chemical composition of fondaparinux, which contains no <italic>N</italic>-acetylated glucosamine and a non-sulfated glucuronic acid residue. Reactivity with antibody LKIV69, which reacts poorly with 6-<italic>O</italic>-sulfated epitopes, was very weak and reflects the high amount of 6-<italic>O</italic>-sulfation in fondaparinux. Reactivity with antibody AO4B08, which needs C5-epimerization, <italic>N</italic>-sulfation, high 6-<italic>O</italic>-sulfation and an internal 2-<italic>O</italic>-sulfated iduronic acid residue, was only moderate/poor, reflecting the lack of an internal 2-<italic>O</italic>-sulfated iduronic acid (<italic>i.e.</italic> flanked by other iduronic acid residues). Reactivity with antibody HS4C3, which requires <italic>N</italic>-, 3-<italic>O</italic>-, and 6-<italic>O</italic>-sulfation, and antibody HS3A8, which requires at least C5-epimerization and <italic>N</italic>- and 2-<italic>O</italic>&#x2013;sulfation, was high, which corresponds with the chemical structure of fondaparinux. Reactivity was also high with antibodies EW3D10 and EW4G2, both defining an as yet undefined, but sulfated oligosaccharide. These data indicate that reactivity with antibodies may provide some chemical information of heparinoids.
<table-wrap id="Tab4"><label>Table&#xA0;4</label><caption><p>Reactivity of anti-heparin antibodies with heparin and fondaparinux (competition ELISA)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#xA0;</th><th>HS4C3</th><th>HS3A8</th><th>HS4E4</th><th>LKIV69</th><th>EW3D10</th><th>EW4G2</th><th>NS4F5</th><th>AO4B08</th><th>RB4EA12</th></tr></thead><tbody><tr><td>Heparin</td><td>0.3&#x2009;&#xB1;&#x2009;0.1</td><td>0.4&#x2009;&#xB1;&#x2009;0.1</td><td>2.7&#x2009;&#xB1;&#x2009;0.1 </td><td>0.2&#x2009;&#xB1;&#x2009;0.0</td><td>0.1&#x2009;&#xB1;&#x2009;0.0</td><td>0.1&#x2009;&#xB1;&#x2009;0.0</td><td>0.1&#x2009;&#xB1;&#x2009;0.0</td><td>1.2&#x2009;&#xB1;&#x2009;0.2</td><td>&lt;0.01</td></tr><tr><td>Fondaparinux</td><td>1.7&#x2009;&#xB1;&#x2009;0.2</td><td>1.3&#x2009;&#xB1;&#x2009;0.1 </td><td>&gt;200</td><td>10.3&#x2009;&#xB1;&#x2009;0.8</td><td>0.2&#x2009;&#xB1;&#x2009;0.0</td><td>1.5&#x2009;&#xB1;&#x2009;0.5 </td><td>11.7&#x2009;&#xB1;&#x2009;0.8 </td><td>12.3&#x2009;&#xB1;&#x2009;3.8</td><td>21.5&#x2009;&#xB1;&#x2009;0.5</td></tr><tr><td>Ratio fondaparinux/heparin</td><td>5.7</td><td>3.3</td><td>&gt;74</td><td>51.5</td><td>2</td><td>15</td><td>117</td><td>10.3</td><td>&gt;2150</td></tr></tbody></table><table-wrap-foot><p>Given are the amounts of heparinoids (micrograms per milliliter), which result in a 50% inhibition of the binding of the anti-heparin antibodies to immobilized HS/heparin (IC<sub>50</sub> values), and the ratio between antibody reactivity with fondaparinux and heparin. Values are given as mean &#xB1; SEM (<italic>n</italic>&#x2009;=&#x2009;3). Antibody EW3D10 showed a strong reactivity with fondaparinux, followed by antibodies HS4C3, HS3A8, and EW4G2. The other antibodies showed a relatively weak or no reactivity.</p></table-wrap-foot></table-wrap></p>
        <p>Reactivity of the anti-heparin antibodies with immobilized heparinoids was supported by immunofluorescence analysis (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). When human renal cryosections were simultaneously incubated with anti-heparin antibodies and heparinoids, staining was completely abolished with those heparinoids, which reacted strongly with the antibodies in ELISA (<italic>e.g.</italic> heparin and sulodexide for antibodies HS4C3 and HS4E4). An obvious decreased staining was noticed for those heparinoids, which reacted moderately with the antibodies (<italic>e.g.</italic> nadroparin for antibody HS4C3), whereas no major differences in staining were observed for those heparinoids, which did not bind to antibodies (<italic>e.g.</italic> nadroparin for antibody HS4E4).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Immunofluorescence staining of human renal cryosections with anti-heparin antibodies HS4C3 and HS4E4 in the absence and presence of heparinoids. Staining was abolished when renal cryosections were incubated with HS4C3 or HS4E4 in the presence of heparin or sulodexide. HS4C3 staining was decreased in the presence of nadroparin, whereas HS4E4 staining was unaffected. <italic>Bar</italic> represents 50&#xA0;&#x3BC;m; magnification is identical for each photograph. <italic>G</italic> Glomerulus, <italic>BC</italic> Bowman&#x2019;s capsule, <italic>T</italic> renal tubule</p></caption><graphic position="anchor" xlink:href="10719_2007_9070_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec14" sec-type="discussion">
      <title>Discussion</title>
      <p>In this study eight heparinoids were characterized by their reactivity with nine different anti-heparin antibodies. All heparinoids showed a distinct antibody-binding profile in line with differences in GAG composition (heparin, HS, CS, DS), molecular weight, and method of preparation. A number of antibodies reacted strongly with certain heparinoids, but not with others. It may therefore be possible to deduce chemical and biological information of a specific heparinoid by virtue of its antibody profile. For instance, antibody NS4F5 showed reactivity with only heparin. This antibody defines a stretch of trisulfated (<italic>N</italic>-, 2-<italic>O</italic>-, and 6-<italic>O</italic>-sulfated) and epimerized disaccharides and therefore defines a highly sulfated heparin domain (Smits <italic>et al.</italic>, unpublished results). The lack of reactivity of the other heparinoids for NS4F5 indicates the absence or the destruction of the domain during their preparation. Absence may hold for sulodexide and danaparoid, which contain HS rather than heparin. Destruction by the depolymerization processes may hold for the LMWHs. In this respect, reactivity with antibody NS4F5 may be indicative for the degree of depolymerization. The antibody profile of the chemically synthesized pentasaccharide fondaparinux is compatible with its chemical structure GlcNS(6OS)&#x2013;GlcA&#x2013;GlcNS(3,6OS)&#x2013;IdoA(2OS)&#x2013;GlcNS(6OS). Reactivity with antibodies HS4C3 and HS3A8 indicates it to contain iduronic acid and <italic>N</italic>-, 2-<italic>O</italic>-, 3-<italic>O</italic>-, and 6-<italic>O</italic>-sulfate residues, whereas poor/no reactivity with antibodies HS4E4, LKIV69, AO4B08, and RB4EA12 indicates the lack of internal 2-<italic>O</italic>-sulfated iduronic acid residues (<italic>i.e.</italic> flanked by other iduronic acids) and <italic>N</italic>-acetylated glucosamine residues. Lack of reactivity with antibody NS4F5 indicates that fondaparinux does not contain a stretch of tri-sulfated disaccharides.</p>
      <p>Next to information on the chemical properties of the heparinoids, the antibody profile may be indicative for their biological activity, <italic>e.g.</italic> the anti-Xa/anti-IIa ratio. This ratio is of essential importance since it is associated with a more predictable anticoagulant effect. The anti-Xa/anti-IIa ratio is 1 for unfractionated heparin, 2&#x2013;4 for LMWHs, 0.5 for sulodexide, and infinite for fondaparinux [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Antibodies such as HS4E4 and AO4B08 (Tables&#xA0;<xref rid="Tab3" ref-type="table">3</xref> and <xref rid="Tab4" ref-type="table">4</xref>), which are highly reactive with heparin and sulodexide, but poorly/not with LMWHs and fondaparinux, likely bind to a heparin domain structure at a site proximal to the pentasaccharide sequence and may be indicative for a high anti-factor IIa activity. These results indicate that when a heparinoid is recognized by antibodies HS4C3, HS3A8, EW3D10, and EW4G2 (which showed a high reactivity with fondaparinux; Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>), as well as by antibodies HS4E4 and AO4B08, the heparinoid is able to form a ternary complex with antithrombin III and factor IIa, resulting in inactivation of both factors Xa and IIa [<xref ref-type="bibr" rid="CR23">23</xref>]. On the other hand, when a heparinoid is recognized by antibodies HS4C3, HS3A8, EW3D10, and EW4G2, but not by antibodies HS4E4 and AO4B08, it is does not contain the heparin domain structure at the site proximal to the pentasaccharide required for factor IIa binding. In this case only factor Xa will be inactivated. When a ratio is calculated from reactivity of heparinoids with antibodies HS4C3 and HS4E4 (indicative for 3-<italic>O</italic>-sulfates and for the presence of domains allowing IIa activity, respectively), and heparin is assigned a ratio of 1, the following numbers are found: dalteparin, 9; nadroparin, 7; enoxaparin, 11; tinzaparin, 11; sulodexide, 0.4; and fondaparinux, &gt;&gt;13 (no antibody HS4E4 reactivity observed). These numbers are in line with the above mentioned anti-Xa/anti-IIa ratios, which were determined by enzymatic assays [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], and indicate that biological characteristics are associated with antibody profiles.</p>
      <p>Heparin-induced thrombocytopenia (HIT) is a major complication in patients administered heparin. Heparin binding to platelet factor 4 (PF4) causes a conformational change in the protein, rendering it antigenic. Susceptible patients develop antibodies to the heparin-PF4 complex, and binding of the antibody-PF4-heparin complex to its receptor on platelets results in platelet activation and aggregation. In addition, platelets are removed by activated immune cells, resulting in thrombocytopenia [<xref ref-type="bibr" rid="CR6">6</xref>]. Highly sulfated domains within heparin/HS are involved in the binding to PF4 [<xref ref-type="bibr" rid="CR31">31</xref>], and an increase in sulfation and size is associated with an increased risk of HIT [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. This may explain why the incidence of HIT is lower in patients treated with LMWHs, danaparoid, or fondaparinux compared to unfractionated heparin [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Antibody NS4F5, which defines a highly sulfated domain, reacted strongly with heparin, but not with the other heparinoids. Reactivity with this antibody may thus be used to obtain information about the risk of a heparinoid to induce HIT.</p>
      <p>Although we have focussed here on the immunoprofiling of heparinoids in the context of anticoagulation, this technique may also be useful to evaluate heparinoids in other settings. Heparin and LMWHs have been used to treat patients with kidney disease since an ameliorating effect on a.o. proteinuria has been found [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Likewise, heparinoids are reported to have anti-tumor and anti-metastatic effects [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], the degree of sulfation being of crucial importance. Heparinase III-digested heparin (highly sulfated fragments), inhibited tumor growth, whereas heparinase I-digested heparin (low sulfated fragments) promoted tumor growth [<xref ref-type="bibr" rid="CR18">18</xref>], underscoring the necessity to characterize the preparation used. In addition to the implementation of these antibodies to characterize the therapeutic potential of heparinoids, they may be used to stage a disease (<italic>e.g.</italic> kidney disease, cancer) characterized by a specific HS profile in tissue, blood, and/or urine.</p>
      <p>Since the antibody profile of the heparinoids used in these studies may be correlated to a specific biological effect, antibodies may be used for the identification and subsequent characterization of the active structures within the heparinoids, which may result in the development of more specific drugs. The antibodies described here may also be used to counteract bleeding in patients administered an overdose of heparinoids. This is generally accomplished by treatment with protamine sulfate [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], but this rather unspecific polycation may cause hypotension, bradycardia, and thrombocytopenia. In addition it may cause other severe side effects including anaphylactic and anaphylactoid reactions, resulting in respiratory distress, circulatory collapse, capillary leak, and pulmonary hypertension [<xref ref-type="bibr" rid="CR26">26</xref>]. There is a need for safer agents that inhibit the anticoagulant activity of heparinoids, and some antibodies described here may be useful, especially those that also react with fondaparinux, which is difficult to inhibit in vivo. It has already been described that antibodies HS4C3 and EW3D10 strongly inhibited heparin-induced anticoagulation (APTT clotting assay) [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Antibody HS4C3 also blocked the anticoagulant activities of heparin and fondaparinux in an anti-factor Xa assay [<xref ref-type="bibr" rid="CR35">35</xref>]. These studies indicate that anti-heparin antibodies may react with heparinoids thereby neutralizing their anticoagulant effect.</p>
      <p>Finally, our antibodies may be used for fast industrial screening of heparinoids. A quality check of heparinoid batches may be performed using the antibodies since each heparinoid shows a specific immunoprofile.</p>
      <p>In conclusion, this study presents a novel way of characterizing heparinoids using immunoprofiling. Reactivity with antibodies was found indicative for chemical and biological aspects of the heparinoids, and may therefore be used for a fast and simple screening of industrial batches for defined characteristics.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgement</title>
      <p>This work was supported by grants from The Netherlands Organization for Scientific Research (NWO; program grant 902-27-292), the International Human Frontier Science Program Organization (HFSP; grant RGP0062/2004-C101), and the Dutch Kidney Foundation (grant C05.2152).</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Achour</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kacem</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dibej</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Skhiri</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bouraoui</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>May</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>One year course of oral sulodexide in the management of diabetic nephropathy</article-title>
          <source>J. Nephrol.</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>568</fpage>
          <lpage>574</lpage>
        </citation>
        <citation citation-type="display-unstructured">Achour A., Kacem M., Dibej K., Skhiri H., Bouraoui S., El May M.: One year course of oral sulodexide in the management of diabetic nephropathy. J. Nephrol. 18, 568&#x2013;574 (2005) <pub-id pub-id-type="pmid">16299683</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baglin</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Barrowcliffe</surname>
              <given-names>T.W.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Guidelines on the use and monitoring of heparin</article-title>
          <source>Br. J. Haematol.</source>
          <year>2006</year>
          <volume>133</volume>
          <fpage>19</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2005.05953.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Baglin T., Barrowcliffe T.W., Cohen A., Greaves M.: Guidelines on the use and monitoring of heparin. Br. J. Haematol. 133, 19&#x2013;34 (2006) <pub-id pub-id-type="pmid">16512825</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bobek</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kovarik</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Antitumor and antimetastatic effect of warfarin and heparins</article-title>
          <source>Biomed. Pharmacother.</source>
          <year>2004</year>
          <volume>58</volume>
          <fpage>213</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biopha.2003.11.007</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bobek V., Kovarik J.: Antitumor and antimetastatic effect of warfarin and heparins. Biomed. Pharmacother. 58, 213&#x2013;219 (2004) <pub-id pub-id-type="pmid">15183845</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Torri</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Structural characterization of low molecular weight heparins</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>1999</year>
          <volume>25</volume>
          <issue>Suppl 3</issue>
          <fpage>17</fpage>
          <lpage>25</lpage>
        </citation>
        <citation citation-type="display-unstructured">Casu B., Torri G.: Structural characterization of low molecular weight heparins. Semin. Thromb. Hemost. 25(Suppl 3), 17&#x2013;25 (1999) <pub-id pub-id-type="pmid">10549712</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Fondaparinux: a new antithrombotic agent</article-title>
          <source>Clin. Ther.</source>
          <year>2002</year>
          <volume>24</volume>
          <fpage>1757</fpage>
          <lpage>1769</lpage>
          <pub-id pub-id-type="doi">10.1016/S0149-2918(02)80077-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cheng J.W.: Fondaparinux: a new antithrombotic agent. Clin. Ther. 24, 1757&#x2013;1769 (2002) <pub-id pub-id-type="pmid">12501872</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>B.H.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia</article-title>
          <source>J. Thromb. Hemost.</source>
          <year>2003</year>
          <volume>1</volume>
          <fpage>1471</fpage>
          <lpage>1478</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1538-7836.2003.00270.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chong B.H.: Heparin-induced thrombocytopenia. J. Thromb. Hemost. 1, 1471&#x2013;1478 (2003) </citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>H.N.</given-names>
            </name>
          </person-group>
          <article-title>Orgaran in heparin-induced thrombocytopenia</article-title>
          <source>Haemostasis</source>
          <year>1992</year>
          <volume>22</volume>
          <fpage>85</fpage>
          <lpage>91</lpage>
        </citation>
        <citation citation-type="display-unstructured">Chong B.H., Magnani H.N.: Orgaran in heparin-induced thrombocytopenia. Haemostasis. 22, 85&#x2013;91 (1992) <pub-id pub-id-type="pmid">1379968</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dennissen</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Jenniskens</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Pieffers</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Versteeg</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Petitou</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Veerkamp</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies</article-title>
          <source>J. Biol. Chem.</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>10982</fpage>
          <lpage>10986</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M104852200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dennissen M.A., Jenniskens G.J., Pieffers M., Versteeg E.M., Petitou M., Veerkamp J.H., van Kuppevelt T.H.: Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J. Biol. Chem. 277, 10982&#x2013;10986 (2002) <pub-id pub-id-type="pmid">11790764</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dietrich</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Shinjo</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Mendes</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gouvea</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Nader</surname>
              <given-names>H.B.</given-names>
            </name>
          </person-group>
          <article-title>Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>1999</year>
          <volume>25</volume>
          <issue>Suppl 3</issue>
          <fpage>43</fpage>
          <lpage>50</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dietrich C.P., Shinjo S.K., Moraes F.A., Castro R.A., Mendes A., Gouvea T.C., Nader H.B.: Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. Semin. Thromb. Hemost. 25(Suppl 3), 43&#x2013;50 (1999) <pub-id pub-id-type="pmid">10549715</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dunn</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Sorkin</surname>
              <given-names>E.M.</given-names>
            </name>
          </person-group>
          <article-title>Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders</article-title>
          <source>Drugs</source>
          <year>1996</year>
          <volume>52</volume>
          <fpage>276</fpage>
          <lpage>305</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dunn C.J., Sorkin E.M.: Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs 52, 276&#x2013;305 (1996) <pub-id pub-id-type="pmid">8841743</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ernst</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Langer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Cooney</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Sasisekharan</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic degradation of glycosaminoglycans</article-title>
          <source>Crit. Rev. Biochem. Mol. Biol.</source>
          <year>1995</year>
          <volume>30</volume>
          <fpage>387</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.3109/10409239509083490</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ernst S., Langer R., Cooney C.L., Sasisekharan R.: Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30, 387&#x2013;444 (1995) <pub-id pub-id-type="pmid">8575190</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fareed</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Leong</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Hoppensteadt</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Jeske</surname>
              <given-names>W.P.</given-names>
            </name>
            <name>
              <surname>Walenga</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wahi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bick</surname>
              <given-names>R.L.</given-names>
            </name>
          </person-group>
          <article-title>Generic low-molecular-weight heparins: some practical considerations</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>2004</year>
          <volume>30</volume>
          <fpage>703</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2004-861513</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fareed J., Leong W.L., Hoppensteadt D.A., Jeske W.P., Walenga J., Wahi R., Bick R.L.: Generic low-molecular-weight heparins: some practical considerations. Semin. Thromb. Hemost. 30, 703&#x2013;713 (2004) <pub-id pub-id-type="pmid">15630677</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farndale</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Buttle</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue</article-title>
          <source>Biochim. Biophys. Acta</source>
          <year>1986</year>
          <volume>883</volume>
          <fpage>173</fpage>
          <lpage>177</lpage>
        </citation>
        <citation citation-type="display-unstructured">Farndale R.W., Buttle D.J., Barrett A.J.: Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta. 883, 173&#x2013;177 (1986) <pub-id pub-id-type="pmid">3091074</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gambaro</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kinalska</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Oksa</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pont&#x2019;uch</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hertlova</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Olsovsky</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Manitius</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fedele</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Czekalski</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Perusicova</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Skrha</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Taton</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Grzeszczak</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Crepaldi</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial</article-title>
          <source>J. Am. Soc. Nephrol.</source>
          <year>2002</year>
          <volume>13</volume>
          <fpage>1615</fpage>
          <lpage>1625</lpage>
          <pub-id pub-id-type="doi">10.1097/01.ASN.0000014254.87188.E5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gambaro G., Kinalska I., Oksa A., Pont&#x2019;uch P., Hertlova M., Olsovsky J., Manitius J., Fedele D., Czekalski S., Perusicova J., Skrha J., Taton J., Grzeszczak W., Crepaldi G.: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13, 1615&#x2013;1625 (2002) <pub-id pub-id-type="pmid">12039991</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jenniskens</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Oosterhof</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brandwijk</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Veerkamp</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies</article-title>
          <source>J. Neurosci.</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>4099</fpage>
          <lpage>4111</lpage>
        </citation>
        <citation citation-type="display-unstructured">Jenniskens G.J., Oosterhof A., Brandwijk R., Veerkamp J.H., van Kuppevelt T.H.: Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J. Neurosci. 20, 4099&#x2013;4111 (2000) <pub-id pub-id-type="pmid">10818145</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="other">Kurup S., Wijnhoven T.J., Jenniskens G.J., Kimata K., Habuchi H., Li J.P., Lindahl U., van Kuppevelt T.H., Spillmann D.: Characterization of anti-heparan sulfate phage-display antibodies AO4B08 and HS4E4. J. Biol. Chem. <bold>282</bold>(29), 21032&#x2013;21042 (2007)</citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linhardt</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Gunay</surname>
              <given-names>N.S.</given-names>
            </name>
          </person-group>
          <article-title>Production and chemical processing of low molecular weight heparins</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>1999</year>
          <volume>25</volume>
          <issue>Suppl 3</issue>
          <fpage>5</fpage>
          <lpage>16</lpage>
        </citation>
        <citation citation-type="display-unstructured">Linhardt R.J., Gunay N.S.: Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25(Suppl 3), 5&#x2013;16 (1999) <pub-id pub-id-type="pmid">10549711</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Shriver</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Venkataraman</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shabrawi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sasisekharan</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>568</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.012578299</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., Sasisekharan R.: Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 99, 568&#x2013;573 (2002) <pub-id pub-id-type="pmid">11805315</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maccarana</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lindahl</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Mode of interaction between platelet factor 4 and heparin</article-title>
          <source>Glycobiology</source>
          <year>1993</year>
          <volume>3</volume>
          <fpage>271</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1093/glycob/3.3.271</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Maccarana M., Lindahl U.: Mode of interaction between platelet factor 4 and heparin. Glycobiology 3, 271&#x2013;277 (1993) <pub-id pub-id-type="pmid">8358152</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mousa</surname>
              <given-names>S.A.</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulants in thrombosis and cancer: the missing link</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>2002</year>
          <volume>28</volume>
          <fpage>45</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2002-20559</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mousa S.A.: Anticoagulants in thrombosis and cancer: the missing link. Semin. Thromb. Hemost. 28, 45&#x2013;52 (2002) <pub-id pub-id-type="pmid">11885025</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Myrup</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kofoed-Enevoldsen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Feldt-Rasmussen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gram</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kluft</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jespersen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Deckert</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus</article-title>
          <source>Lancet</source>
          <year>1995</year>
          <volume>345</volume>
          <fpage>421</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(95)90403-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Myrup B., Hansen P.M., Jensen T., Kofoed-Enevoldsen A., Feldt-Rasmussen B., Gram J., Kluft C., Jespersen J., Deckert T.: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345, 421&#x2013;422 (1995) <pub-id pub-id-type="pmid">7853952</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neely</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Lenhart</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>Tinzaparin sodium: a low-molecular-weight heparin</article-title>
          <source>Am. J. Health-Syst. Pharm.</source>
          <year>2002</year>
          <volume>59</volume>
          <fpage>1426</fpage>
          <lpage>1436</lpage>
        </citation>
        <citation citation-type="display-unstructured">Neely J.L., Carlson S.S., Lenhart S.E.: Tinzaparin sodium: a low-molecular-weight heparin. Am. J. Health-Syst. Pharm. 59, 1426&#x2013;1436 (2002) <pub-id pub-id-type="pmid">12166042</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petitou</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Boeckel</surname>
              <given-names>C.A.</given-names>
            </name>
          </person-group>
          <article-title>A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?</article-title>
          <source>Angew. Chem. Int. Ed. Engl.</source>
          <year>2004</year>
          <volume>43</volume>
          <fpage>3118</fpage>
          <lpage>3133</lpage>
          <pub-id pub-id-type="doi">10.1002/anie.200300640</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Petitou M., van Boeckel C.A.: A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed. Engl. 43, 3118&#x2013;3133 (2004) <pub-id pub-id-type="pmid">15199558</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polkinghorne</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>L.P.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients</article-title>
          <source>Am. J. Kidney Dis.</source>
          <year>2002</year>
          <volume>40</volume>
          <fpage>990</fpage>
          <lpage>995</lpage>
          <pub-id pub-id-type="doi">10.1053/ajkd.2002.36331</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Polkinghorne K.R., McMahon L.P., Becker G.J.: Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am. J. Kidney Dis. 40, 990&#x2013;995 (2002) <pub-id pub-id-type="pmid">12407644</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poplawska</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Szelachowska</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Topolska</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wysocka-Solowie</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kinalska</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria</article-title>
          <source>Diabetes Res. Clin. Pract.</source>
          <year>1997</year>
          <volume>38</volume>
          <fpage>109</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-8227(97)00096-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Poplawska A., Szelachowska M., Topolska J., Wysocka-Solowie B., Kinalska I.: Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res. Clin. Pract. 38, 109&#x2013;114 (1997) <pub-id pub-id-type="pmid">9483374</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porsche</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>Z.R.</given-names>
            </name>
          </person-group>
          <article-title>Allergy to protamine sulfate</article-title>
          <source>Heart Lung</source>
          <year>1999</year>
          <volume>28</volume>
          <fpage>418</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1016/S0147-9563(99)70031-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Porsche R., Brenner Z.R.: Allergy to protamine sulfate. Heart Lung. 28, 418&#x2013;428 (1999) <pub-id pub-id-type="pmid">10580216</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prydz</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dalen</surname>
              <given-names>K.T.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and sorting of proteoglycans</article-title>
          <source>J. Cell Sci.</source>
          <year>2000</year>
          <volume>113</volume>
          <issue>Pt 2</issue>
          <fpage>193</fpage>
          <lpage>205</lpage>
        </citation>
        <citation citation-type="display-unstructured">Prydz K., Dalen K.T.: Synthesis and sorting of proteoglycans. J. Cell Sci. 113(Pt 2), 193&#x2013;205 (2000) <pub-id pub-id-type="pmid">10633071</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagedal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sundstrom</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Bjornsen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fauchald</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Brosstad</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>A single dose of dalteparin effectively prevents clotting during haemodialysis</article-title>
          <source>Nephrol. Dial. Transplant.</source>
          <year>1999</year>
          <volume>14</volume>
          <fpage>1943</fpage>
          <lpage>1947</lpage>
          <pub-id pub-id-type="doi">10.1093/ndt/14.8.1943</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sagedal S., Hartmann A., Sundstrom K., Bjornsen S., Fauchald P., Brosstad F.: A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol. Dial. Transplant. 14, 1943&#x2013;1947 (1999) <pub-id pub-id-type="pmid">10462275</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sasisekharan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Shriver</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Venkataraman</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Narayanasami</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Roles of heparan&#x2013;sulphate glycosaminoglycans in cancer</article-title>
          <source>Nat. Rev. Cancer</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>521</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc842</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U.: Roles of heparan&#x2013;sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521&#x2013;528 (2002) <pub-id pub-id-type="pmid">12094238</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skrha</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Perusicova</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pont'uch</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Oksa</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients</article-title>
          <source>Diabetes Res. Clin. Pract.</source>
          <year>1997</year>
          <volume>38</volume>
          <fpage>25</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-8227(97)00076-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Skrha J., Perusicova J., Pont'uch P., Oksa A.: Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res. Clin. Pract. 38, 25&#x2013;31 (1997) <pub-id pub-id-type="pmid">9347243</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stringer</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>Specific binding of the chemokine platelet factor 4 to heparan sulfate</article-title>
          <source>J. Biol. Chem.</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>20508</fpage>
          <lpage>20514</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.272.33.20508</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stringer S.E., Gallagher J.T.: Specific binding of the chemokine platelet factor 4 to heparan sulfate. J. Biol. Chem. 272, 20508&#x2013;20514 (1997) <pub-id pub-id-type="pmid">9252363</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugahara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kitagawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <year>2000</year>
          <volume>10</volume>
          <fpage>518</fpage>
          <lpage>527</lpage>
          <pub-id pub-id-type="doi">10.1016/S0959-440X(00)00125-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sugahara K., Kitagawa H.: Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr. Opin. Struct. Biol. 10, 518&#x2013;527 (2000) <pub-id pub-id-type="pmid">11042448</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szelachowska</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Poplawska</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Topolska</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kinalska</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Grimaldi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Szelanowska</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jopdska</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients</article-title>
          <source>Curr. Med. Res. Opin.</source>
          <year>1997</year>
          <volume>13</volume>
          <fpage>539</fpage>
          <lpage>545</lpage>
        </citation>
        <citation citation-type="display-unstructured">Szelachowska M., Poplawska A., Topolska J., Kinalska I., Grimaldi M., Szelanowska M., Jopdska J.: A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr. Med. Res. Opin. 13, 539&#x2013;545 (1997) <pub-id pub-id-type="pmid">9169256</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamsma</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Woude</surname>
              <given-names>F.J.</given-names>
            </name>
            <name>
              <surname>Lemkes</surname>
              <given-names>H.H.</given-names>
            </name>
          </person-group>
          <article-title>Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy</article-title>
          <source>Nephrol. Dial. Transplant.</source>
          <year>1996</year>
          <volume>11</volume>
          <fpage>182</fpage>
          <lpage>185</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tamsma J.T., van der Woude F.J., Lemkes H.H.: Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol. Dial. Transplant. 11, 182&#x2013;185 (1996) <pub-id pub-id-type="pmid">8649631</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ten Dam</surname>
              <given-names>G.B.</given-names>
            </name>
            <name>
              <surname>Kurup</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Westerlo</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Versteeg</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Lindahl</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Spillmann</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>3-<italic>O</italic>-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3</article-title>
          <source>J. Biol. Chem.</source>
          <year>2006</year>
          <volume>281</volume>
          <fpage>4654</fpage>
          <lpage>4662</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ten Dam G.B., Kurup S., van de Westerlo E.M., Versteeg E.M., Lindahl U., Spillmann D., van Kuppevelt T.H.: 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3. J. Biol. Chem. 281, 4654&#x2013;4662 (2006) <pub-id pub-id-type="pmid">16373349</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turnbull</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Hopwood</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>A strategy for rapid sequencing of heparan sulfate and heparin saccharides</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>2698</fpage>
          <lpage>2703</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.96.6.2698</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Turnbull J.E., Hopwood J.J., Gallagher J.T.: A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc. Natl. Acad. Sci. U.S.A. 96, 2698&#x2013;2703 (1999) <pub-id pub-id-type="pmid">10077574</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turpie</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Pentasaccharides</article-title>
          <source>Semin. Hematol.</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>158</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="doi">10.1053/shem.2002.34091</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Turpie A.G.: Pentasaccharides. Semin. Hematol. 39, 158&#x2013;171 (2002) <pub-id pub-id-type="pmid">12124678</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lest</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Versteeg</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Veerkamp</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A&#x2013;silver staining in agarose gels</article-title>
          <source>Anal. Biochem.</source>
          <year>1994</year>
          <volume>221</volume>
          <fpage>356</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="doi">10.1006/abio.1994.1425</pub-id>
        </citation>
        <citation citation-type="display-unstructured">van de Lest C.H., Versteeg E.M., Veerkamp J.H., van Kuppevelt T.H.: Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A&#x2013;silver staining in agarose gels. Anal. Biochem. 221, 356&#x2013;361 (1994) <pub-id pub-id-type="pmid">7529008</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westerlo</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Smetsers</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Dennissen</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Linhardt</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Veerkamp</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Muijen</surname>
              <given-names>G.N.</given-names>
            </name>
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Human single chain antibodies against heparin: selection, characterization, and effect on coagulation</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>2427</fpage>
          <lpage>2433</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V99.7.2427</pub-id>
        </citation>
        <citation citation-type="display-unstructured">van de Westerlo E.M., Smetsers T.F., Dennissen M.A., Linhardt R.J., Veerkamp J.H., van Muijen G.N., van Kuppevelt T.H.: Human single chain antibodies against heparin: selection, characterization, and effect on coagulation. Blood 99, 2427&#x2013;2433 (2002) <pub-id pub-id-type="pmid">11895775</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pijl</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Woude</surname>
              <given-names>F.J.</given-names>
            </name>
            <name>
              <surname>Geelhoed-Duijvestijn</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Frolich</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Meer</surname>
              <given-names>F.J.</given-names>
            </name>
            <name>
              <surname>Lemkes</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Es</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Danaparoid sodium lowers proteinuria in diabetic nephropathy</article-title>
          <source>J. Am. Soc. Nephrol.</source>
          <year>1997</year>
          <volume>8</volume>
          <fpage>456</fpage>
          <lpage>462</lpage>
        </citation>
        <citation citation-type="display-unstructured">van der Pijl J.W., van der Woude F.J., Geelhoed-Duijvestijn P.H., Frolich M., van der Meer F.J., Lemkes H.H., van Es L.A.: Danaparoid sodium lowers proteinuria in diabetic nephropathy. J. Am. Soc. Nephrol. 8, 456&#x2013;462 (1997) <pub-id pub-id-type="pmid">9071714</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Dennissen</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Venrooij</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Hoet</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Veerkamp</surname>
              <given-names>J.H.</given-names>
            </name>
          </person-group>
          <article-title>Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney</article-title>
          <source>J. Biol, Chem</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>12960</fpage>
          <lpage>12966</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.273.21.12960</pub-id>
        </citation>
        <citation citation-type="display-unstructured">van Kuppevelt T.H., Dennissen M.A., van Venrooij W.J., Hoet R.M., Veerkamp J.H.: Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J. Biol, Chem, 273, 12960&#x2013;12966 (1998) <pub-id pub-id-type="pmid">9582329</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cusmano</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Venturelli</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma</article-title>
          <source>Biochim. Biophys. Acta.</source>
          <year>1995</year>
          <volume>1243</volume>
          <fpage>49</fpage>
          <lpage>58</lpage>
        </citation>
        <citation citation-type="display-unstructured">Volpi N., Cusmano M., Venturelli T.: Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim. Biophys. Acta. 1243, 49&#x2013;58 (1995) <pub-id pub-id-type="pmid">7827107</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wijnhoven</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Lensen</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Rops</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Vlag</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kolset</surname>
              <given-names>S.O.</given-names>
            </name>
            <name>
              <surname>Bangstad</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hoven</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Berden</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Heuvel</surname>
              <given-names>L.P.</given-names>
            </name>
            <name>
              <surname>Kuppevelt</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics</article-title>
          <source>Am. J. Kidney Dis.</source>
          <year>2006</year>
          <volume>48</volume>
          <fpage>250</fpage>
          <lpage>261</lpage>
          <pub-id pub-id-type="doi">10.1053/j.ajkd.2006.05.003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wijnhoven T.J., Lensen J.F., Rops A.L., van der Vlag J., Kolset S.O., Bangstad H.J., Pfeffer P., van den Hoven M.J., Berden J.H., van den Heuvel L.P., van Kuppevelt T.H.: Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics. Am. J. Kidney Dis. 48, 250&#x2013;261 (2006) <pub-id pub-id-type="pmid">16860191</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>